Eli Lilly
- All
- News
- Videos
-
Weight-Loss Drugs Set To Get Cheaper In India As Semaglutide Patents Expire
The cost of popular weight-loss injections like Ozempic and Wegovy is expected to fall in India as patents on semaglutide expire in March 2026, paving the way for generic versions and wider access to anti-obesity medications.
-
Novo Nordisk's CagriSema Delivers 23% Weight Loss In Trial But Still Trails Eli Lilly's Tirzepatide
CagriSema is a once-weekly subcutaneous injection, which is being investigated by Novo Nordisk as a treatment for adults with overweight or obesity.
-
On Camera, Trump's Drug Event Paused As Man Faints At White House
President Donald Trump had a jump scare at the White House when a man collapsed while standing just behind him during an event in the Oval Office.
-
Rising Diabetes In US Kids: Can Mounjaro Be The Answer? New Study Says Yes
A new study reveals Mounjaro may help children as young as 10 manage Type 2 diabetes, significantly reducing blood sugar and weight, with Eli Lilly pushing to expand its use beyond adults.
-
Mounjaro Is In India, Ozempic Coming Soon. How Are We Taking Trump's 'Fat Shot' Drugs?
Mounjaro has arrived in India, and the demand is rising fast. But will it stick? We tried to find out
-
Eli Lilly Launches Weight Loss Drug In India: What You Should Know About Mounjaro
Mounjaro for Weight Loss: By influencing multiple body systems simultaneously, tirzepatide offers a powerful approach to managing both diabetes and weight.
-
'Once-A-Week Shot' Weight-Loss Drug Mounjaro Launched In India By Eli Lilly
Eli Lilly and Company (India) on Thursday said it has launched a first-of-its-kind medication for obesity and type 2 diabetes in the country after obtaining approval from the Central Drugs Standard Control Organisation (CDSCO).
-
Eli Lilly's Zepbound Drug Likely To Dominate Global Obesity Market: Report
Eli Lilly's Zepbound drug holds potential to dominate the global obesity market due to its superior efficacy and strategic market expansion, a report showed on Tuesday.
-
Weight-Loss Drugs Under EU Scanner Amid Suicide Risk Claims
The European Union's drugs regulator has asked pharma companies including Novo Nordisk A/S and Eli Lilly & Co. for more information as it reviews the potential risk of suicidal thoughts associated with a new class of weight-loss medicines.
-
Groundbreaking New Alzheimer's Drug Slows Progression Of The Disease, Finds Study
The medication had a successful clinical trial and is expected to be approved by the Food and Drug Administration this fall.
-
Weight-Loss Drugs Set To Get Cheaper In India As Semaglutide Patents Expire
The cost of popular weight-loss injections like Ozempic and Wegovy is expected to fall in India as patents on semaglutide expire in March 2026, paving the way for generic versions and wider access to anti-obesity medications.
-
Novo Nordisk's CagriSema Delivers 23% Weight Loss In Trial But Still Trails Eli Lilly's Tirzepatide
CagriSema is a once-weekly subcutaneous injection, which is being investigated by Novo Nordisk as a treatment for adults with overweight or obesity.
-
On Camera, Trump's Drug Event Paused As Man Faints At White House
President Donald Trump had a jump scare at the White House when a man collapsed while standing just behind him during an event in the Oval Office.
-
Rising Diabetes In US Kids: Can Mounjaro Be The Answer? New Study Says Yes
A new study reveals Mounjaro may help children as young as 10 manage Type 2 diabetes, significantly reducing blood sugar and weight, with Eli Lilly pushing to expand its use beyond adults.
-
Mounjaro Is In India, Ozempic Coming Soon. How Are We Taking Trump's 'Fat Shot' Drugs?
Mounjaro has arrived in India, and the demand is rising fast. But will it stick? We tried to find out
-
Eli Lilly Launches Weight Loss Drug In India: What You Should Know About Mounjaro
Mounjaro for Weight Loss: By influencing multiple body systems simultaneously, tirzepatide offers a powerful approach to managing both diabetes and weight.
-
'Once-A-Week Shot' Weight-Loss Drug Mounjaro Launched In India By Eli Lilly
Eli Lilly and Company (India) on Thursday said it has launched a first-of-its-kind medication for obesity and type 2 diabetes in the country after obtaining approval from the Central Drugs Standard Control Organisation (CDSCO).
-
Eli Lilly's Zepbound Drug Likely To Dominate Global Obesity Market: Report
Eli Lilly's Zepbound drug holds potential to dominate the global obesity market due to its superior efficacy and strategic market expansion, a report showed on Tuesday.
-
Weight-Loss Drugs Under EU Scanner Amid Suicide Risk Claims
The European Union's drugs regulator has asked pharma companies including Novo Nordisk A/S and Eli Lilly & Co. for more information as it reviews the potential risk of suicidal thoughts associated with a new class of weight-loss medicines.
-
Groundbreaking New Alzheimer's Drug Slows Progression Of The Disease, Finds Study
The medication had a successful clinical trial and is expected to be approved by the Food and Drug Administration this fall.
